PH12015502652A1 - Methods for treatment of inflammatory conditions using s-[4-(3-fluoro-3-methylbutyryloxy) but-2-ynyl] 6alpha, 9alpha-difluoro-17alpha-(furan-2-yl) carbonyloxy-11beta -hydroxy-16alpha-methyl-3-oxoandrosta-1,4-diene-17beta -carbothioate. - Google Patents
Methods for treatment of inflammatory conditions using s-[4-(3-fluoro-3-methylbutyryloxy) but-2-ynyl] 6alpha, 9alpha-difluoro-17alpha-(furan-2-yl) carbonyloxy-11beta -hydroxy-16alpha-methyl-3-oxoandrosta-1,4-diene-17beta -carbothioate.Info
- Publication number
- PH12015502652A1 PH12015502652A1 PH12015502652A PH12015502652A PH12015502652A1 PH 12015502652 A1 PH12015502652 A1 PH 12015502652A1 PH 12015502652 A PH12015502652 A PH 12015502652A PH 12015502652 A PH12015502652 A PH 12015502652A PH 12015502652 A1 PH12015502652 A1 PH 12015502652A1
- Authority
- PH
- Philippines
- Prior art keywords
- oxoandrosta
- methylbutyryloxy
- carbothioate
- ynyl
- carbonyloxy
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 230000004968 inflammatory condition Effects 0.000 title abstract 2
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 title 1
- -1 carbonyloxy-11beta -hydroxy-16alpha-methyl-3-oxoandrosta-1,4-diene-17beta -carbothioate Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 150000001441 androstanes Chemical class 0.000 abstract 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
- C07J3/005—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom the carbon atom being part of a carboxylic function
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Otolaryngology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1881MU2013 | 2013-05-28 | ||
| PCT/IN2014/000359 WO2014192027A1 (en) | 2013-05-28 | 2014-05-28 | Methods for treatment of inflammatory conditions using s-[4-(3-fluoro-3-methylbutyryloxy) but-2-ynyl] 6alpha, 9alpha-difluoro-17alpha-(furan-2-yl) carbonyloxy-11beta -hydroxy-16alpha-methyl-3-oxoandrosta-1,4-diene-17beta -carbothioate. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12015502652A1 true PH12015502652A1 (en) | 2016-03-07 |
Family
ID=51300796
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH12015502652A PH12015502652A1 (en) | 2013-05-28 | 2015-11-26 | Methods for treatment of inflammatory conditions using s-[4-(3-fluoro-3-methylbutyryloxy) but-2-ynyl] 6alpha, 9alpha-difluoro-17alpha-(furan-2-yl) carbonyloxy-11beta -hydroxy-16alpha-methyl-3-oxoandrosta-1,4-diene-17beta -carbothioate. |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US9458187B2 (enExample) |
| EP (1) | EP3004133B1 (enExample) |
| JP (1) | JP6366696B2 (enExample) |
| KR (1) | KR20160030085A (enExample) |
| CN (1) | CN105431445A (enExample) |
| AU (1) | AU2014272640B2 (enExample) |
| BR (1) | BR112015029530A8 (enExample) |
| CA (1) | CA2912400A1 (enExample) |
| EA (1) | EA027831B9 (enExample) |
| ES (1) | ES2664019T3 (enExample) |
| IL (1) | IL242658A0 (enExample) |
| MX (1) | MX2015016283A (enExample) |
| MY (1) | MY179214A (enExample) |
| PH (1) | PH12015502652A1 (enExample) |
| SG (1) | SG11201509680TA (enExample) |
| UA (1) | UA117248C2 (enExample) |
| WO (1) | WO2014192027A1 (enExample) |
| ZA (1) | ZA201508640B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105431445A (zh) | 2013-05-28 | 2016-03-23 | 太阳医药高级研究有限公司 | 使用S-[4-(3-氟-3-甲基丁酰氧基)丁-2-炔基]6α，9α-二氟-17α-(呋喃-2-基)羰氧基-11β-羟基-16α-甲基-3-氧代雄甾-1，4-二烯-17β-硫代羧酸酯治疗炎性疾病的方法 |
| SG11201706104XA (en) * | 2015-01-31 | 2017-08-30 | Sun Pharma Advanced Res Co Ltd | CRYSTALLINE FORM OF S-(4-(3-FLUORO-3-METHYLBUTYRYLOXY)BUT-2-YNYL)6a,9a-DIFLUORO-17a,-(FURAN-2-YL)CARBONYLOXY-11ß-HYDROXY-16a-METHY1-3-OXOANDROSTA-1,4-DIENE-17ß-CARBOTHIOATE |
| CN106279341A (zh) * | 2015-05-11 | 2017-01-04 | 正大天晴药业集团股份有限公司 | 一种糠酸氟替卡松的制备方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE887518A (fr) | 1980-02-15 | 1981-08-13 | Glaxo Group Ltd | Cartothioates d'androstanes |
| AU2003263575A1 (en) | 2002-06-20 | 2004-01-06 | Sun Pharmaceutical Industries Limited | Convenient synthesis of s-fluoromethyl 6alpha, 9alpha-difluoro-11beta-hydroxy-16alpha- methyl-17alpha-propionyloxy-3-oxoandrosta-1, 4-diene-17beta-carbothioate |
| GB0225287D0 (en) | 2002-10-30 | 2002-12-11 | Glaxo Group Ltd | Novel compounds |
| TWI374147B (en) * | 2006-01-27 | 2012-10-11 | Sun Pharma Advance Res Company Ltd | Novel 11β-hydroxyandrosta-4-ene-3-ones |
| CN105431445A (zh) | 2013-05-28 | 2016-03-23 | 太阳医药高级研究有限公司 | 使用S-[4-(3-氟-3-甲基丁酰氧基)丁-2-炔基]6α，9α-二氟-17α-(呋喃-2-基)羰氧基-11β-羟基-16α-甲基-3-氧代雄甾-1，4-二烯-17β-硫代羧酸酯治疗炎性疾病的方法 |
-
2014
- 2014-05-28 CN CN201480030607.2A patent/CN105431445A/zh active Pending
- 2014-05-28 EA EA201592283A patent/EA027831B9/ru not_active IP Right Cessation
- 2014-05-28 AU AU2014272640A patent/AU2014272640B2/en not_active Ceased
- 2014-05-28 MY MYPI2015704326A patent/MY179214A/en unknown
- 2014-05-28 US US14/893,655 patent/US9458187B2/en not_active Expired - Fee Related
- 2014-05-28 WO PCT/IN2014/000359 patent/WO2014192027A1/en not_active Ceased
- 2014-05-28 ES ES14750012.8T patent/ES2664019T3/es active Active
- 2014-05-28 SG SG11201509680TA patent/SG11201509680TA/en unknown
- 2014-05-28 BR BR112015029530A patent/BR112015029530A8/pt not_active Application Discontinuation
- 2014-05-28 UA UAA201512888A patent/UA117248C2/uk unknown
- 2014-05-28 MX MX2015016283A patent/MX2015016283A/es unknown
- 2014-05-28 CA CA2912400A patent/CA2912400A1/en not_active Abandoned
- 2014-05-28 KR KR1020157033778A patent/KR20160030085A/ko not_active Withdrawn
- 2014-05-28 JP JP2016516309A patent/JP6366696B2/ja not_active Expired - Fee Related
- 2014-05-28 EP EP14750012.8A patent/EP3004133B1/en not_active Not-in-force
-
2015
- 2015-11-18 IL IL242658A patent/IL242658A0/en unknown
- 2015-11-24 ZA ZA2015/08640A patent/ZA201508640B/en unknown
- 2015-11-26 PH PH12015502652A patent/PH12015502652A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2014272640B2 (en) | 2018-04-05 |
| MX2015016283A (es) | 2016-03-11 |
| AU2014272640A1 (en) | 2015-11-26 |
| CN105431445A (zh) | 2016-03-23 |
| EA027831B9 (ru) | 2017-12-29 |
| JP2016520122A (ja) | 2016-07-11 |
| EP3004133B1 (en) | 2018-03-07 |
| BR112015029530A2 (pt) | 2017-07-25 |
| JP6366696B2 (ja) | 2018-08-01 |
| WO2014192027A1 (en) | 2014-12-04 |
| CA2912400A1 (en) | 2014-12-04 |
| IL242658A0 (en) | 2016-02-01 |
| EP3004133A1 (en) | 2016-04-13 |
| BR112015029530A8 (pt) | 2019-12-17 |
| US9458187B2 (en) | 2016-10-04 |
| US20160102117A1 (en) | 2016-04-14 |
| SG11201509680TA (en) | 2015-12-30 |
| MY179214A (en) | 2020-11-02 |
| EA027831B1 (ru) | 2017-09-29 |
| EA201592283A1 (ru) | 2016-04-29 |
| KR20160030085A (ko) | 2016-03-16 |
| ES2664019T3 (es) | 2018-04-18 |
| UA117248C2 (uk) | 2018-07-10 |
| ZA201508640B (en) | 2017-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019501321A1 (en) | Methods of treating or preventing cholesterol related disorders | |
| EA201690473A1 (ru) | Комбинированный состав двух противовирусных соединений | |
| PH12016501192A1 (en) | Tetrahydropyridopyrazines modulators of gpr6 | |
| MY186547A (en) | 4?-fluoro-2?-methyl substituted nucleoside derivatives | |
| GT201500235A (es) | Estra -1,3,5 (10) , 16- tetraeno -3-carboxamidas para la inhibicion de la 17b-hidroxiesteroide deshidrogenasa (akr1c3) | |
| NZ711192A (en) | Process for making benzoxazepin compounds | |
| CA2929436C (en) | Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases | |
| BR112015029462A8 (pt) | Inibidores de quinase | |
| EA201500931A1 (ru) | Производные пиридин-4-ила | |
| MX349548B (es) | Compuestos de tienopirimidina. | |
| EA201690227A1 (ru) | Азаиндольные соединения, их получение и способы их применения | |
| MX2015016332A (es) | Inhibidores de alk biciclicos fusionados. | |
| EA201690763A1 (ru) | Лечение рака поджелудочной железы | |
| UA113988C2 (xx) | Спосіб стабілізації бета-напівгідрату штукатурного гіпсу | |
| PH12015502652A1 (en) | Methods for treatment of inflammatory conditions using s-[4-(3-fluoro-3-methylbutyryloxy) but-2-ynyl] 6alpha, 9alpha-difluoro-17alpha-(furan-2-yl) carbonyloxy-11beta -hydroxy-16alpha-methyl-3-oxoandrosta-1,4-diene-17beta -carbothioate. | |
| MX2015016603A (es) | Composiciones de corticosteroides. | |
| EA201591449A1 (ru) | Способы получения противораковых композиций | |
| MX2016006807A (es) | Derivados de imidazol. | |
| PH12016500788A1 (en) | Compounds for the treatment of diabetes and disease complications arising from same | |
| MX2016005511A (es) | Intermediarios y metodos para sintetizar derivados de calicheamicina. | |
| PH12017501360A1 (en) | Crystalline form of s-(4-3-fluoro-3-methylbutyryloxy)but-2-ynyl)6a,9a-difluoro-17a,-(fluran-2-yl) carbonyloxy-11b-hydroxy-16a-methy1-3-oxoandrosta-1,4-diene-17b-carbothioate | |
| EA201270727A1 (ru) | Пуриновые соединения | |
| TR201314937A2 (tr) | Viral enfeksiyonların tedavisine yönelik bir kompozisyon. | |
| IN2013MU01524A (enExample) | ||
| IN2013MU02279A (enExample) |